Intensified Biocatalytic Production of Enantiomerically
An intensified, industrially-relevant strategy for the production of enantiopure halophenylalanines has been developed using the novel combination of a cyanobacterial phenylalanine ammonia lyase (PAL) and ammonium carbamate reaction buffer. The process boasts STYs up to >200g L -1 d -1 , ees ≥98% and simplified catalyst / reaction buffer preparation and work up.
Ring-halogenated phenylalanine analogues are a class of unnatural amino acids used in variety of research endeavours in medicinal chemistry and chemical biology. Compounds such as 3-fluoro-Lphenylalanine, for example, have been identified as key components of antifungal di-and tripeptides, effective against multidrug-resistant strains of the opportunistic human pathogen Candida albicans. 1 This same molecule, along with its 4-fluoro regioisomer, has been shown to improve the catalytic properties of lipase under industrially-relevant conditions via incorporation into the polypeptide in lieu of natural proteinogenic amino acids. 2 In a similar vein, genetic incorporation of para-halo-L-phenylalanines into a maltose binding protein is reported to enable site-specific tagging following Suzuki-Miyaura coupling with a furanylboronic acid. 3 This coupling method can also be used to functionalise bromo-and chloro-phenylalanine derivatives to create drug molecules such as the biaryl dipeptidyl peptidase IV inhibitors, novel candidates for the management of type II diabetes. 4, 5 The use of enzymes to carry out highly chemo-, regio-and enantioselective syntheses is an attractive strategy in terms of minimising the environmental impact (e.g. from side product generation, protection/deprotection steps) of chemical processes. This is due to their ability to mediate challenging reactions under mild aqueous conditions, reducing both energy input and organic solvent waste. Enzyme catalysts are built from natural primary metabolites in a renewable manner using facile recombinant DNA technologies. Biocatalysts with a well characterised ability to produce halogenated arylalanines are the phenylalanine ammonia lyase (PAL) enzymes, which allow the selective addition of free ammonia to inexpensive and readily-available cinnamic acid derivatives. 4, [6] [7] [8] [9] [10] [11] This process is 100% atom efficient, relying solely on a catalytic tyrosine and the 4-methylideneimidazole-5-one (MIO) prosthesis, thus mitigating the need for expensive and wasteful cofactor supplementation / regeneration. Due to the unique chemistry, difficult to mimic with traditional synthetic methods, PALs have been used in the synthesis of the pharmaceutical intermediates 4-bromo-4 and 2-chloro-L-phenylalanine. 9, 12 The latter process -used in the industrial-scale production of the antihypertension drug perindopril -is a rare example of an intensified reaction, with a space-time yield
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Despite the utility of halophenylalanines and the demonstrated efficiency of PAL-catalysed reactions, 6, 7, 10 there exist very few examples of large scale syntheses of these compounds using this method. Herein we report a superior intensified method for the preparative scale amination of readily-accessible halocinnamates to give enantiopure amino acids in good purity with a chromatography-free workup, employing a novel ammonia source. Previous studies with ammonia lyase biocatalysts revealed that they suffer from inactivation and can require lengthy formulation procedures for effective use. 13, 14 In the interests of simplifying catalyst preparation, the previously characterised enzyme from the cyanobacterium Anabaena variabilis (AvPAL) 15 was used due to its demonstrated thermostability 16 and conversion of diverse cinnamate derivatives. [8] [9] [10] Through various optimisation steps, a method was arrived at by which 150 mM 3-fluorocinnamic acid 1b could be converted to 93% (details of the optimisation steps are reported in the ESI). These reaction parameters were: 20 mg mL -1 lyophilised Escherichia coli whole cells harbouring the AvPAL biocatalyst, 13% w/v ammonia solution pH adjusted with carbon dioxide (pH 9.5), 30°C, 200 rpm, 22 h. Despite the improvements in reaction parameters, the method did, however, require a large quantity of CO 2 to form an ammonium carbonate solution of sufficient concentration and pH. As this would constitute a major problem and increase costs in an industrial setting, an alternative ammonia source was sought for further investigations. Use of ammonium carbamate was considered due to its high solubility, volatility, low cost and unbuffered pH ~10. As an initial test, a 150 mM amination reaction of 3-fluorocinnamic acid 1b was conducted with 4 M ammonium carbamate, affording 98% conversion within a 22 h time period indicating both an increase in reaction productivity and a shift in equilibrium. Similar improvements have been observed with different biocatalytic systems 17 and may be due to the potential of the carbamate counter-ion to act as a slow release source of additional ammonia, providing more of this reactant. The effect of substrate loading with this new system was tested with solutions of 50-350 mM substrate (Table 1 ) and it was found that, even up to 300 mM substrate concentration, ≥97% conversion could be obtained (dropping to 81% at 350 mM). All conversions were calculated from combined soluble and insoluble fractions of the reaction mixture, since the substrate was found not to be fully soluble at concentrations >200 mM.
In light of the efficiency conferred by the new reaction buffer, preparative scale (4 mL) reactions were set up with a variety of cinnamic acid derivatives (1a-i, Table 2 ), previously reported to be substrates for AvPAL. In each case, reaction parameters were altered so as to allow >95% conversion with the 4 M ammonium carbamate and 20 mg mL -1 catalyst at 30 o C. It was observed that, for fluorinated compounds (1a-c, g and h) 100 mM substrate concentration was sufficient, while for the less soluble substrates (such as the chloro-substituted 1d-f and i), concentrations of 50 mM were more appropriate. In each set of compounds the least soluble para-isomer seemed to give less than the desired conversion after 1 day -a situation remedied by additional reflected the purity of the product as previously estimated by HPLC. As a demonstration of the industrial viability of our method, a gram-scale synthesis of (S)-2b as a model target product was 12 The process presented here also features higher catalyst productivity, a lack of requirement for batch addition of substrate or catalyst and ready availability of the volatile ammonium donor salt, without the need for pH adjustment or lengthy ion-exchange work-up methods. The environmental factor (E factor) of the reaction is also calculated to be ~5, which is far lower than the typical values for fine chemical synthesis, an improvement on other PAL-mediated reactions and borderline for bulk chemical production.
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This improved protocol proved also to be compatible with our recently reported telescopic combination of cinnamic acid synthesis and PAL hydroamination. 19 The Knoevenagel-Doebner condensation of 3-fluorobenzaldehyde 3 and malonic acid was performed under optimised conditions. The crude reaction mixture (~1 M concentration of 1b) was then used directly as starting material for subsequent biotransformation reactions. Different volume ratios of the reaction mixture and ammonium carbamate solution were (Table 4 ).
Conversions to (S)-2b were found to be slightly lower than (but comparable to) the corresponding reactions with pure 1b, with equally excellent ee values. The lowered conversions are likely due to the increased concentration of DMSO from the initial chemical reaction, shown previously to be mildly inhibitory to the AvPAL reaction. 19 This result constitutes an improvement of this extended approach to amino acid synthesis, allowing greater telescopic loading of the first reaction mixture into a more intensified hydroamination to yield the final product, thus incurring less overall waste from the biocatalytic step. Furthermore, our intensified biotransformation process was also applied to the synthesis of the pharmaceutical building block biarylalanine 4 starting from 3-bromocinnamic acid 1j (Scheme 2). The chemo-enzymatic approach combining PAL-mediated hydroamination with Suzuki-Miyaura coupling was previously employed for the synthesis of 4-aryl substituted phenylalanines, 4 but this process required an ion exchange chromatography step to remove the high concentration of ammonium sulphate and unreacted cinnamic acid substrate. The downstream process could be considerably mitigated by adopting ammonium carbamate under optimised conditions: almost full conversion (96%) of 1j to (S)-2j was achieved, leaving a negligible amount of starting material (ESI). The crude product obtained after removal of ammonium carbamate by sublimation could be used without further treatment for N-protection followed by Suzuki-Miyaura coupling, 4 affording 4 in 24% overall isolated yield from 1j (Scheme 2). The structural moiety of 3-aryl substituted phenylalanine is present in several pharmaceutical ingredients and building blocks, such as selective Nmethyl-D-aspartate receptor (NMDA) antagonists for treatment of Parkinson's disease, 20, 21 angiotensin-converting enzyme 2 (ACE-2) modulators for weight disorders 22 and chemotactic peptides. 23 In conclusion, an improved and simplified method for the production of various halogenated amino acids in excellent enantiomeric excess has been reported. The catalyst of choice is a recombinant, stable wild-type PAL produced from renewable feedstocks, harboured within lyophilised whole cells to mitigate lengthy catalyst purification and/or immobilisation steps.
